Journal
MOLECULAR ASPECTS OF MEDICINE
Volume 72, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.mam.2020.100844
Keywords
Liquid biopsy; Circulating miRNA; Lung cancer; Standardization
Funding
- Innovative Medicines Initiative (IMI) Joint Undertaking from the European Union's Seventh Framework Programme (FP7/2007-2013) [115,749]
- EFPIA companies
Ask authors/readers for more resources
Liquid biopsy holds great promise to complement traditional analysis on cancerous tissue during clinical management of cancer: screening of patients, (early) disease diagnosis, prognosis, therapy selection as well as early response to treatment and disease monitoring. Among emerging circulating biomarkers, cell-free miRNA (cfmiRNA) may have potential in detecting lung cancer and following the course of the disease. Furthermore, several studies highlighted the possibility to utilize these regulatory RNAs to obtain prognostic information as well as to verify patient's response towards treatment. However, despite these findings, cfmiRNA is not used in the clinical practice as biomarkers to date, since their clinical utility and validity has not been confirmed in prospective clinical studies yet. In addition, there is no consensus on standardized (pre)analytical procedures. In this review, we present an overview of cfmiRNA biomarker candidates for clinical management of lung cancer and we discuss the issue of assay standardization.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available